Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: metastatic castration-resistant prostate
New Prostate Cancer Agent Improves Survival by Nearly 5 Months!
Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy! An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading →
Posted in Cancer, Prostate cancer
|
Tagged abiraterone, AFFIRM, bicalutamide, cabazitaxel, Casodex, docetaxel, Drogenil, flutamide, Jevtana, MDV3100, Medivation, metastatic castration-resistant prostate, Prostate cancer, Provenge, sipuleucel-T, Survival, Taxotere, Zytiga
|
Comments Off on New Prostate Cancer Agent Improves Survival by Nearly 5 Months!
